BrainTransporter™ dramatically improves antibody delivery to the brain
BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the ...
Le Lézard7h
BrainTransportertm dramatically improves antibody delivery to the brain
BioArctic AB (publ) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in ...
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend Insights - Technavio
Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...
Asia One1d
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...
BioSpace2d
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...
Bernstein Reaffirms Their Buy Rating on Daiichi Sankyo Company (DSKYF)
Bernstein analyst Miki Sogi maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) yesterday and set a price target ...
The Pharma Letter5d
BRIEF—Eisai completes rolling submission to US FDA for Leqembi maintenance dosing
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) ...
precisionmedicineonline5d
Eisai Completes Rolling BLA Submission for Subcutaneous Leqembi Maintenance Treatment
Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...
pharmaphorum5d
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
The application covers a once-weekly autoinjector formulation of the anti-amyloid antibody Leqembi (lecanemab), after a ...
Le Lézard5d
Shining a Light on Familial Hypercholesterolemia: ABC Promotes Awareness During National Sudden Cardiac Arrest Awareness Month
As part of its ongoing commitment to raise awareness about heart health and address health disparities, the Association of Black Cardiologists (ABC) highlights Familial Hypercholesterolemia (FH) ...
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...